RxSight annual r&d spending
2020
2021
2022
2023
2024
2025
RxSight R&D Spending Growth & History (RXST)
RxSight's r&d spending was $38.5M for fiscal 2025.
View full RxSight company overviewRxSight annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $38.5M | $4.2M | +12.17% |
| 2024 | 2024-12-31 | $34.4M | $5.3M | +18.30% |
| 2023 | 2023-12-31 | $29.1M | $3.1M | +11.82% |
| 2022 | 2022-12-31 | $26.0M | $1.5M | +6.05% |
| 2021 | 2021-12-31 | $24.5M | $2.6M | +11.69% |
| 2020 | 2020-12-31 | $21.9M | — | — |
RxSight quarterly r&d spending
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $9.2M | −$980,000 | −9.59% |
| Q1 2026 | 2026-03-31 | $9.5M | −$895,000 | −8.63% |
| Q4 2025 | 2025-12-31 | $8.9M | −$302,000 | −3.28% |
| Q3 2025 | 2025-09-30 | $9.1M | $222,000 | +2.51% |
| Q2 2025 | 2025-06-30 | $10.2M | $1.9M | +23.23% |
| Q1 2025 | 2025-03-31 | $10.4M | $2.3M | +29.09% |
| Q4 2024 | 2024-12-31 | $9.2M | $1.9M | +25.42% |
| Q3 2024 | 2024-09-30 | $8.8M | $1.7M | +24.46% |
| Q2 2024 | 2024-06-30 | $8.3M | $890,000 | +12.03% |
| Q1 2024 | 2024-03-31 | $8.0M | $823,000 | +11.42% |
| Q4 2023 | 2023-12-31 | $7.3M | $659,000 | +9.86% |
| Q3 2023 | 2023-09-30 | $7.1M | $713,000 | +11.16% |
| Q2 2023 | 2023-06-30 | $7.4M | $1.2M | +19.53% |
| Q1 2023 | 2023-03-31 | $7.2M | $489,000 | +7.28% |
| Q4 2022 | 2022-12-31 | $6.7M | $766,000 | +12.95% |
| Q3 2022 | 2022-09-30 | $6.4M | $1.0M | +18.80% |
| Q2 2022 | 2022-06-30 | $6.2M | −$371,000 | −5.65% |
| Q1 2022 | 2022-03-31 | $6.7M | $76,000 | +1.14% |
| Q4 2021 | 2021-12-31 | $5.9M | — | — |
| Q3 2021 | 2021-09-30 | $5.4M | −$424,000 | −7.31% |
| Q2 2021 | 2021-06-30 | $6.6M | $1.5M | +29.09% |
| Q1 2021 | 2021-03-31 | $6.6M | — | — |
| Q3 2020 | 2020-09-30 | $5.8M | — | — |
| Q2 2020 | 2020-06-30 | $5.1M | — | — |
RxSight r&d spending trends
Over the last five fiscal years, RxSight's r&d spending increased from $21.9M to $38.5M, a change of $16.6M. The latest reported quarter, Q2 2026, shows $9.2M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review RxSight source filings ↗